

Commercial Medicines Unit

NHS England

2nd Floor

Rutland House

Runcorn

Cheshire

WA7 2ES

**Friday 2 December 2022**

**Invitation to offer for NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals**

**Offer reference number: CM/PHR/22/5675**

**Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

Dear Sir/Madam, please note the information below in relation to mexiletine:

The original tender product listing included the below descriptions:

|  |  |  |
| --- | --- | --- |
| DBC059 | MEXILETINE CAPSULES 200MG | 100 |
| DBC051 | MEXILETINE CAPSULES 167MG | 100 |

This is a notification that product descriptions have been amended as detailed below and a new version of Document No. 05b (ii) Tender Product listing and usage - CM\_PHR\_22\_5675\_02 has been issued.

|  |  |  |
| --- | --- | --- |
| DBC059 | MEXILETINE HYDROCHLORIDE CAPSULES 200MG (MEXILETINE BASE 167MG) | 100 |
| DBC051 | MEXILETINE (NAMUSCLA) CAPSULES 167MG (200MG HYDROCHLORIDE) | 100 |

Please ensure that offer/s relating to mexiletine are made against the appropriate NPC code in Selectt.

In addition, we would like to bring the following information to your attention:

|  |  |  |
| --- | --- | --- |
| DBC068 | MEXILETINE CAPSULES 50MG | 84 |
| DBC067 | MEXILETINE CAPSULES 100MG | 84 |
| DBC059 | MEXILETINE HYDROCHLORIDE CAPSULES 200MG (MEXILETINE BASE 167MG) | 100 |

**The above products are being tendered for the treatment of documented ventricular arrhythmias which, in the judgement of the physician, are considered as life-threatening.**

|  |  |  |
| --- | --- | --- |
| DBC051 | MEXILETINE (NAMUSCLA) CAPSULES 167MG (200MG HYDROCHLORIDE) | 100 |

**The above product is being tendered for the Authorised orphan indication: the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.**

CMU will share the same explanation at the tender evaluation stage. If an award is made against the above products, this information will be communicated to Participating Authorities before the framework commencement date.

Yours faithfully



Katie Noonan

Operations Adviser and Developing Commercial Practitioner

Branded, Biosimilars and IV Fluids Procurement Support